A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1081-1087

  Norum, J ^a   Olsen, J A ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Colorectal cancer; Cost effectiveness; Follow up

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; CANCER RECURRENCE; CLINICAL PROTOCOL; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THORAX RADIOGRAPHY;

EID: 0030726732     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008265614183     Document Type: Article

References (38)

1. Cancer in Norway 1993. The Cancer Registry of Norway, Institute for Epidemiological Cancer Research, Oslo 1996.
2. Cuzick J. Once only sigmoidoscopy. Oncol Prac 1995; 3: 12-5.
3. Martin EW, Minton JP, Carey LC CEA directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985; 202: 310-7.
4. Tveit KM, Dahl O, Gerner T. Chemotherapy in colorectal cancer. Recommendations from Norwegian Gastrointestinal Cancer Group. J Nor Med Assoc 1996; 116: 357-60.
5. Pihl E, Hughes ESR, McDermot FT et al. Disease free survival and recurrence after resection of colorectal cancer. J Surg Oncol 1981; 16: 333-41.
6. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-62.
7. Schuppisser JP. Patientselektion und leistungsfähigkeit der tumornachsorge beim operierten kolorektalen karzinom. Schweiz Rundschau Med 1991; 80: 791-5.
8. Cochrane JP, Williams TJ, Gaber RG, Slack WW. Value of outpatient follow-up after curative surgery for carcinoma of the large bowel. BMJ 1980; 280: 593-5.
9. Martin EW, Cooperman M, Carey C, Minton JP. Sixty secondlook procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res 1980; 28: 389-94.
10. Camunas J, Enriquez JM, Devesa JM et al. Value of follow-up in the management of of recurrent colorectal cancer. Eur J Surg Oncol 1991; 17: 530-5.
11. Beart RW, O'Connell MJ. Postoperative follow-up of patients with carcinoma of the colon. Mayo Clin Proc 1983; 58: 361-3.
12. Lennon T, Houghton J, Northover J. Post-operative CEA monitoring and second-look surgery in colorectal cancer. Br J Cancer 1994; 70: 16.
13. Brada M. Strategies for follow-up of patients with common malignancies. Impact of follow-up policies on survival and quality of life. In: American Society of Clinical Oncology (ASCO) Educational Book, 32nd annual meeting, May 18-21, 1996, Philadelphia, PA, 324-7.
14. Bruinvels DJ, Stiggelbout AM, Kievit J et al. Follow-up patients with colorectal cancer. Ann Surg 1994; 219: 174-82.
15. Norum J, Gerner T, Bergan A. Lange O. Follow-up in colorectal cancer. Guidelines from the Norwegian Gastrointestinal Cancer Group (NGICG). J Nor Med Assoc 1997; in press.
16. Wanebo HJ, Rao B, Pinsky CM et al. The use of the preoperative carcinombryonic antigen level as a prognostic indicator to complement pathologic staging. N Engl J Med 1978; 299: 448-51.
17. Berge I, Ekelund C, Mellner BP. Carcinoma of the colon and rectum in a defined population, an epidemiological, clinical and post-mortem investigation of colorectal cancer and co-existing benign polyps in Malmø, Sweden. Acta Chir Scand 1973; 438: 1-86.
18. Minton JP, Hoehn JL, Gerber DM et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284-90.
19. Kievit J, van de Velde CJH. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow up evaluation. A Markov analysis. Cancer 1990; 63: 2580-7.
20. The Tariff for Medical Specialists 1996-97. The Norwegian Medical Association, Oslo 1996.
21. The Tariff of Public Out-patient Treatment Valid from January 1st 1997. The National Insurrance Administration, Oslo, 1996.
22. Luce BR, Elixhauser A. Standards for the Socioeconomic Evaluation of Health Care Services. Berlin: Springer-Verlag 1990.
23. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol 1997; 8: 65-70.
24. Epstein RJ. Does the breast dollar make sense? Eur J Cancer 1992; 28: 486-91.
25. Deveney KE, Way LW. Follow-up of patients with colorectal cancer. Am J Surg 1984; 148: 717-22.
26. Beart RW, O'Connel MJ. Postoperative follow-up of patients with cancer of the colon. Mayo Clin Proc 1983; 58: 361-3.
27. Sugarbaker PH, Gianola FJ, Dweyer A, Neuman NR. A simplified plan for follow-up for patients with colon and rectal cancer supported by prospective studies of laboratory and radiological test results. Surgery 1987; 102: 79-87.
28. Norfleet RG. Postoperative follow-up of patients with colorectal cancer. Am J Gastroenterol 1992; 87: 404.
29. Moffat FL, Ketcham AS. Comprehensive surveillance after curative surgery for adenocarcinoma of the colon. Am J Gastroenterol 1991; 86: 939-40.
30. Kelly CJ, Daly JM. Colorectal cancer. Principles of postoperative follow-up. Cancer 1992; 70: 1397-408.
31. Wanebo HJ, Llaneras M, Martin T. Prospectiv monotoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet 1989; 169: 479-85.
32. McCall JL, Black RB, Rich CA et al. The value of serum carcinoembyonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37: 875-81.
33. Bast RC, Bates S, Bredt AB et al. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77.
34. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66-73.
35. Martin EW, Cooperman M, Carey LC, Minton JP. Sixty second look procedures indicated primarily by rise in serial carcinoembyonic antigen. J Surg Res 1980; 28: 389-94.
36. Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease. A cost-utility analysis. Eur J Cancer 1996; 32A: 1510-7.
37. O'Dweyer PJ, Mojzisik C, McCabe DP et al. Reoperation directed by carcinoembryonic antigen level, the importance of a through pre-operative evaluation. Am J Surg 1988; 155: 227-31.
38. Moertel CG, Flemming TR, Macdonald JS et al. An evaluation of the carcinogenic antigen (CEA). Test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-7.